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1. Literature review 
 
 
Kidney transplantation is the superior treatment for patients 
with end-stage renal disease that can withstand surgery and 
immunosuppressive medication. Kidney transplantation has 
proven to improve life quality and expectancy in addition to 
reducing health care costs compared to hemo- or peritoneal 
dialysis. Kidney transplantations are increasing in number and 
currently about 240 kidney transplantations are done yearly in 
Finland1. Most common causes of end-stage renal disease, and 
thus indications for kidney transplantation, in Finland include: 
diabetic nephropathy, pyelonephritis and polycystic kidney 
disease2. Common complications  after kidney transplantation 
include delayed graft function (DGF), acute rejection and 
urologic complications.  
 
 
1.1 Organ donors 
 
Donation after brain death (DBD) is the principal donor type in 
Finland. In Finland, brain death is diagnosed through 
comprehensive neurologic assessment with absence of brain 
stem reflexes, followed by the apnea test. Also, the cause or 
pathophysiological mechanism of brain death has to be known. 
CT angiography might also be used in unclear situations3. In 
Finland over 85% of kidney grafts are from DBD donors and the 
rest are from living donors. The amount of living donor kidneys 
has been rising in recent years but is low compared to amounts 
worldwide (about 40%)1. Currently in Finland a relative or a 
person living in the same household can act as an organ donor. 
2 
 
   
 
If no such donor exists, any fully mentally competent adult can 
act as an organ donor. Transplantation results from living donors 
are better compared to DBD donors, because living donors are 
not affected by brain death induced changes and long cold 
ischemia time. Recent international registry studies reported 
DGF in approximately 26% of deceased-donor recipients and 3-
5% in living-donor recipients4. 
 
Globally due to organ shortage the use of marginal organs has 
increased. Extended criteria donors (ECD) refer to kidney grafts 
with a relative risk of 1.70 or more for graft failure compared 
with DBD donors5. Commonly used ECD donor characteristics are 
age over 60 years or age 50-59 with two of the following three 
criteria: history of hypertension, serum creatinine over 133 
µmol/l or death from cerebrovascular accident. ECD organs have 
a higher risk for DGF and rejection6. 
 
Donation after circulatory death (DCD) is rising but is not used in 
Finland due to DBD organs supplying the demand. DCD organs 
do not suffer from injuries mediated by brain death but are 
affected by prolonged warm ischemia time during asystole and 
organ procurement. DCD kidneys have higher rates of DGF but 
might have similar long-term outcomes compared to DBD 
kidneys7.  
 
 
1.2 Effects of brain-death 
 
During brain death, ischemia in brainstem releases a burst of 
catecholamines to maintain cerebral perfusion pressure. This is 
often referred to as a catecholamine storm, characterised by 
higher cardiac output and vascular resistance leading to 
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hypertension. After sympathetic activation subsides and 
vasodilation occurs, the donor can become hemodynamically 
unstable. This can lead to compromised perfusion of organs, 
which can then lead to acidosis and elevated levels of lactate and 
glucose. These changes reflect a shift from aerobic to anaerobic 
metabolism8. 
 
Regional vascular beds can autoregulate their perfusion and 
have different threshold blood pressures where their ability to 
do so weakens. The brains and coronaries appear to lose 
autoregulation between 30-50 mmHg mean arterial pressure 
(MAP), while the mammalian kidney loses autoregulation at 
approximately MAP 70 mmHg. After autoregulation is lost, the 
organ blood flow declines in a linear fashion as blood pressure 
falls. In patients with long history of hypertension or critical 
atherosclerosis, the fall is likely to occur at a higher blood 
pressure9,10. This could indicate that these donors should have 
higher MAP goals. Recommended MAP over 60-70 mmHg by 
many guidelines for the treatment of organ donor is not based 
on randomized controlled trials (RCT)11. MAP recommendations 
are based on general critical care guidelines. 
 
Use of catecholamines to maintain donor blood pressure is 
widely used, but they should be administered at low doses. 
Catecholamines raise blood pressure by vasoconstriction, which 
could cause renal artery vasoconstriction and decrease renal 
blood flow in hypotensive patients. In a 2004 multicenter RCT, 
low-dose dopamine was confirmed to improve immediate graft 
function after kidney transplantation in DBD donors. In kidneys 
with cold ischemia time (CIT) over 17h the beneficial effect was 
enhanced12. the beneficial effects of dopamine have been 
proposed to be due to more stable hemodynamics and poorly 
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known cytoprotective effects. RCTs comparing different 
vasoactive drugs are lacking11.  
 
During brain death, the hypothalamic-pituitary axis ceases to 
function which effects systemic hormone levels. Reduction of 
vasopressin levels leads to diabetes insipidus, worsening 
hypovolemia and hemodynamic stability. Desmopressin, a 
synthetic analog of vasopressin, is widely used in organ donor 
care to maintain fluid balance and hemodynamics. Declining 
thyroid hormone levels can affect cellular metabolism, causing 
acidosis. Thyroid hormones can also be linked to the decline of 
cardiocirculatory function, but studies have failed to show 
thyroid hormone therapy to improve kidney function post-
transplantation. Cortisol is an anti-inflammatory hormone and 
declining levels can aggravate inflammation and immunologic 
activation in the donor. Treating kidney donors with steroids 
might improve outcomes after transplantation. Steroid 
treatment has been shown in experimental kidney 
transplantation settings to reduce rejection rates, inflammatory 
cell infiltration and have improved graft survival8. 
 
Brain death has notable effects on inflammatory responses and 
immune activation. Complex interactions between vascular 
endothelium, the complement and coagulation system are 
behind inflammatory events of brain death. Endothelial activity 
facilitates cell migration enabling location of inflammatory cells. 
complement factor levels have been studied in kidneys from 
brain dead donors and increased C3-levels shown to correlate 
clinically with worse renal transplant function8.  
 
Thromboplastin is released in cerebral damage. This starts fibrin 
clotting through the extrinsic pathway. Also, enhanced systemic 
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platelet activation has been observed. Blood clots can cause 
damage by blocking microcirculation and causing tissue hypoxia.  
Cytokine levels  are higher in cadaver donors compared to living 
donors13. Antigen-independent (innate) immune system 
mediated injury occurs during brain death in the donor. It is 
thought to have enhanced or triggering effects on allograft 
rejection14. There has also been conflicting results in kidney 
inflammation after brain death, where kidney biopsies prior to 
organ retrieval showed no difference in major inflammatory 
markers compared to living donor kidneys15. 
 
Organ donor care takes place at various hospitals and standards 
of care can vary. Diagnosis of brain death takes place 
substantially later than the pathophysiological effects on the 
body occur. This and getting research permits for brain-dead 
donors treatment interventions can lead to difficulties 
conducting research. One study reported that mild hypothermia 
34-35 Celsius compared to normothermia in DBD donors 
reduced the rate of DGF (28% vs 39%) in a 370 organ donor 
study16. Hormonal resuscitation involving methylprednisolone, 
vasopressin and triiodothyronine/L‐thyroxine was shown in a 
retrospective analysis of the United Network of Organ sharing 
(UNOS) database to increase organ yield and improve graft 
survival after 1 year6. Hormonal resuscitation might be more 
beneficial to hemodynamically unstable patients11. Organ donor 
vital care compared between UNOS and Finnish organ donor 
guideline is presented below in table 1. Hormonal resuscitation 
and vasopressors are compared in table 2. 
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Organ donor care UNOS Finnish organ 
donor care 
guideline 
MAP, mmHg 60-100 ≥ 60-65 
Central venous pressure, mmHg 4-10 ≤ 8  
Arterial blood gas pH 7.3-7.45 7.35-7.45 
PaO2:FiO2 >300 >300 
Serum sodium, mmol/l 135-155 137-145 
Blood glucose, mmol/l < 8.3 5-8  
Urine output, ml/kg/h 0.5-3 0.5-3 
Table 1. Organ donor vital care comparison between UNOS and Finnish organ donor care guideline17,18. 
Hormonal 
resuscitation and 
vasopressors 
UNOS Finnish 
organ 
donor 
guideline 
Eurotransplant  NHS 
guideline 
Vasopressors one vasoactive 
and low dose 
(dopamine ≤10 
µg/kg/min, 
phenylephrine 
≤60 µg/kg/min, 
noradrenaline 
≤10 
µg/kg/min) 
dopamine 
2-10 
µg/kg/min 
Dopamin 3-6 
µg/kg/min or 
noradrenaline < 
0.2 µg/kg/min, 
avoid adrenaline 
and 
phenylephrine 
dopamine 
(preferred) 
or 
dobutamine 
if required 
Desmopressin consider in 
diabetes 
insipidus 
0.2-0.8 µg 
if urine 
output > 
3ml/kg/h 
2-4 µg bolus if 
diuresis 
>5ml/kg/h 
1-4 µg iv 
titrated to 
effect if 
diuresis 
>4ml/kg/h 
Vasopressin Vasopressin 1 
unit bolus: 0.5-
4.0 unit/h 
infusion 
0.5-2 
units/h 
inotropic and 
vasopressive 
support 
0.5-4 
units/hour 
Methylprednisolone 15mg/kg 1000mg dosage not 
discussed 
15mg/kg 
(max 
1000mg) 
T3/T4 T3 4µg bolus 
and 3µg/h 
infusion 
by cardiac 
surgeon’s 
demand: 
UNOS T3-
protocol or 
T4 20µg 
bolus and 
10 µg/h 
infusion 
- - 
 
Table 2. Hormonal resuscitation and vasopressors compared with UNOS 6,18- , Finnish17- , Eurotransplant19- 
and NHS20 guidelines. 
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1.3 Ischemia-Reperfusion injury 
 
During organ procurement, preservation and transplantation 
the kidney graft is affected by various damaging mechanisms. 
Prior to this, grafts from DBD donors have been influenced by 
the damaging effects of brain death. After procurement the graft 
is flushed with preservation solution and cooled to 4 degrees 
Celsius. This stage is referred to as cold ischemia. During 
transplantation the kidney is removed from the preservation 
solution to perform vascular anastomoses, and this time prior to 
opening of vessels is referred to as warm ischemia. Opening the 
circulation into the graft initiates reperfusion. Damage from 
these different stages is referred to as ischemia-reperfusion (IR) 
injury.   
 
During cold ischemia, hypoxia damages endothelial cell function, 
increasing vascular permeability and causing transcriptional 
reprogramming. Hypoxia damages mitochondria and 
accelerates the production of oxygen radicals. Oxygen radicals 
disrupt intracellular metabolism and cause damage to cell 
membranes. Hypoxia also activates cell death programs and 
necrotic cells produce cytokines leading to inflammation.  
 
Declamping of the vessels initiates reperfusion, enabling the 
activation of innate and adaptive immune responses, causing an 
influx of cells leading to vascular congestion, activation of the 
complement, clotting cascades and thrombosis. Combined, this 
microvascular dysfunction can result in a no-reflow 
phenomenon in capillaries where, despite adequate 
macrovascular perfusion, microvascular perfusion is insufficient  
for tissue oxygen delivery. Dendritic cells may launch direct 
allorecognition in kidney injury. Dendritic cells present antigens 
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to recipients T cells, initiating the activation of adaptive immune 
system21,22. IR injury may culminate in DGF, leading to greater 
graft immunogenicity predisposing the allograft to acute and 
chronic rejection23. 
 
 
1.4 Delayed graft function definitions 
 
DGF is most commonly defined as the requirement for dialysis 
within seven days of kidney transplantation. However, 18 
different definitions for DGF can be found in literature mostly 
based on dialysis and/or creatinine levels24. This can complicate 
study comparison. Comparing graft function and survival with 10 
different definitions of DGF showed that no definition was 
superior in predicting graft outcomes25. Different DGF 
definitions are presented below on Table 325. 
 
Dialysis-based  
The requirement for dialysis in the first postoperative week 
The requirement for dialysis in the first postoperative week excluding the first 24 
hr 
The requirement for two or more episodes of dialysis in the first postoperative 
week  
The requirement for dialysis in the first 10 days postoperatively  
Creatinine-based 
Failure of a fall in serum creatinine of 10% on 3 consecutive days in the first 
postoperative week  
Serum creatinine at postoperative day 7 221 µmol/l 
Serum creatinine at postoperative day 10 221 µmol/l  
Fall in ratio of creatinine of postoperative days 1 and 2 of at least 30% 
Combination 
Dialysis in first week or failure of creatinine to fall in first 24 hr 
Dialysis in the first week or serum creatinine at postoperative day 7 221 µmol/l 
       Table 3. Different DGF definitions. 
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Defining DGF as the use of dialysis in the first postoperative week 
is most widely used and clinically feasible. It is also used in this 
study. As a downside, indications for dialysis post-operatively 
(e.g. hyperkalemia, fluid overload, uremia) can vary between 
centers and physicians. Postoperative graft function can also be 
influenced by acute rejection, infections and surgical 
complications. Biopsy should be considered after 10 days of 
impaired graft function4. Biopsy can differentiate between DGF 
and acute rejection. Nashan et al. showed that biopsy revealed 
the cause of impaired graft function to be acute rejection instead 
of DGF in 17% of cases4.  
 
 
1.5 Delayed graft function risk factors 
 
Risk factors for DGF can be attributed to different stages of the 
transplantation process. Firstly, donor factors play an important 
role. 64% of the variability in renal allograft function 6 months 
after transplantation can be attributed to the donor kidney26. 
After procurement the graft is predisposed to cold and warm 
ischemia followed by reperfusion. After reperfusion recipient 
factors affect graft outcome. 
 
In the recent years, the usage of marginal organs (ECD and 
DCD) has increased the incidence of DGF. Current prediction 
models for DGF overestimate the incidence of DGF. DGF risk 
factors are presented in Table 44. Vasoactives are compared in 
Table 5. RCTs comparing vasopressors are lacking and they are 
often used in combinations in donors. Vasoactive drugs are 
used to control brain death induced hemodynamic changes and 
improve organ perfusion. They can also decrease organ 
perfusion by increasing peripheral vascular resistance and 
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therefore low doses are recommended. Noradrenaline has 
shown mixed results in graft function and outcomes. In 
addition, the effects can be dose-dependent. No benefit for 
DGF prevention can be concluded from noradrenaline27,28, 
dobutamine29 and phenylephrine29 usage. 
 
Donor Recipient Preservation and 
Immunology 
Age Male gender Cold ischemia 
time 
BMI BMI Warm ischemia 
time 
Deceased vs living 
donation 
Black race HLA mismatches 
Increasing donor serum 
creatinine 
Duration of dialysis  
History of hypertension Pretransplant blood 
pressure 
 
ECD and DCD donors Previous transplant  
Diabetes Diabetes  
       Table 4. Donor risk factors for DGF.4 
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Vasoactives and Desmopressin  DGF 
Low dose dopamine 4 µg/kg/min Decreases DGF incidence, 
Improves graft survival if CIT > 17 
h12 
Desmopressin No difference in DGF but might 
improve graft survival6,30 
Vasopressin No effect on DGF, increases organ 
yield31  
Noradrenaline Might improve graft survival and 
reduce graft rejection27,28 
Phenylephrine, adrenaline, 
dobutamine 
Generally recommended in 
severe shock.29  
     Table 5. Vasoactives and Desmopressin effects on DGF. 
 
 
1.6 Clinical significance of delayed graft function 
 
In a 2008 meta-analysis DGF was associated with a 41% 
increased risk of graft loss at 3,2 years, 38% increase in the risk 
of acute rejection in the first year and resulted in higher serum 
creatinine concentrations at 3,5 years of follow-up. No 
difference was seen in patient survival at 5 years of follow-up32. 
DGF has detrimental effects on long-term graft survival, but 
maybe not on patient survival. As DGF eventually may lead to 
graft loss, it will cause patients to resume dialysis. The survival 
of patients is better with a transplanted kidney than that of 
patients on dialysis, which could lead to a difference in survival 
on patients who lost their graft. DGF is associated with higher 
risk of graft loss independently of acute rejection. DGF is linked 
to chronic allograft nephropathy which is likely responsible for 
the inferior graft survival4.  
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DGF is associated with prolonged hospitalization, higher 
transplantation costs and adverse effects on transplant 
recipients33,34. On average, patients with DGF were hospitalized 
for 10 days longer than those with early graft function34.  
 
Organ transplantation provides a unique window of opportunity 
to treat only the organ. Organ donor studies have shown donor 
hypothermia16, low-dose dopamine12 and shorter cold ischemia 
time35,36 to reduce DGF. Also, guideline-based organ donor 
intensive care and hormonal resuscitation have increased organ 
yield. Machine perfusion, where the kidney graft is connected to 
a perfusion device and continuously pumped with a solution at 
temperatures 1-10 degrees Celsius, has been shown to decrease 
DGF incidence37,38.  
 
 
2. Materials and methods 
 
This study is a part of research project “Intra-graft coagulation 
events in clinical renal transplantation and delayed graft 
function” (ClinicalTrials.gov NCT02568696). The main object of 
this study is to assess which organ donor factors predispose to 
delayed graft function. Factors related to the graft recipient 
were not included in this study. 84 organ donors and 100 kidneys 
were included, consequently 16 donors donated both kidneys. 
Kidney transplants were performed during years 2015-16. All 
kidney transplants in Finland are performed at Helsinki 
University Hospital, Department of Transplantation and Liver 
Surgery. Kidney procurement was performed at various 
hospitals in Finland with a team from Helsinki University hospital 
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of transplantation. 11 kidneys were received through Nordic 
countries organ sharing network ScandiaTransplant.  
 
Only patients having their first kidney transplanatation were 
accepted to the study. Prior to the kidney transplantation, 
patients were in hemodialysis or peritoneal dialysis. 
Immunosuppression was achieved with cyclosporin, 
methylprednisolone and mycophenolate mofetil. Patients with 
other immunosuppressant medications and patients with prior 
HLA-immunisation (PRA over 30) were excluded from this study. 
Also, patients that had used heparin or fondaparinux during the 
last two weeks before surgery for other indications than 
anticoagulation during hemodialysis were excluded. 
 
HUS and the ethics committee approved this study (Dnro 
64/13/03/02/2015). Data collected from patients is confidential 
and patient identification data was removed before data-
analysis. Data collection started November 2017 and data-
analysis was done in March 2019. Data was collected from the 
electronic medical record software and anesthesia, ICU and 
organ donor sheets. 
 
The following data were recorded from organ donors: age, sex, 
weight, height, hypertensive disease, medications before ICU 
admission, multiorgan/kidney only donor, time of the 
declaration of brain death, and the cause of brain death. 
 
From ICU stay, the following parameters were tracked: time of 
admission, history of hypotension (MAP <65 mmHg), urine 
output 12 hours before surgery, urine output during organ 
procurement, organ perfusion time and the use of dopamine, 
dobutamine, noradrenalin, adrenalin, phenylephrine, 
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vasopressin and desmopressin. Donor intensive care was carried 
out in accordance to Finnish treatment guide for organ donors17. 
 
The latest available laboratory results from the ICU were used 
for creatinine, hemoglobin, thrombocyte count and 
thromboplastin time (PT). We were not able to get all the above-
mentioned data from the 10 organ donors that were received 
through ScandiaTransplant. At least age, sex, BMI, cause of 
death and creatinine, ICU stay duration and desmopressin use 
were available from all donors. Clinical end points in this study 
were DGF and acute rejection during the three months follow 
up. 
 
 
2.1 Statistical Analysis 
 
Continuous data are expressed as medians with ranges, and 
categorical data as frequency with percentage. Statistical 
significance was tested with the non-parametric Wilcoxon and 
Mann-Whitney tests. Categorical data were tested with Pearson 
Chi-Square test, excluding the use of noradrenalin, which was 
tested with Fisher´s exact test. Data are presented as median 
and range. The α-level was 0.05 for all statistical tests. 
 
3. Results 
 
89 kidney donors were included in this study. 50 (60%) of donors 
were male and 34 (41%) female. Median age was 60 years (range 
11 - 80). Median BMI was 25 kg/m2 (range 18-40). Surprisingly, 
one donor had metformin medication even though usually 
donor diabetes is a contraindication to for kidney donation.  
15 
 
   
 
Causes of brain death are presented in Figure 1 and the 
distribution of donors in different hospitals in Figure 2, 
respectively. 
 
Figure 1. Donor causes of death. SAH = subarachnoid hemorrhage, TBI = traumatic brain injury 
such as subdural hematoma and others = meningitis, anoxia, stroke. 
 
 
Figure 2.  Donor hospitals presented with donor percentages. 
 
27 %
24 %
36 %
13 %
CAUSES OF DEATH
SAH ICH TBI Others
13 %
22 %
2 %
11 %12 %
5 %
5 %
19 %
11 %
DONOR HOSPITALS
Meilahti Töölö Muu HUS
TAYS KYS TYKS
OYS Keskussairaalat ScandiaTransplant
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45 (54%) of organ donors were multiorgan donors and 39 (46%) 
donated only one or two kidneys. 55 (65%) donors had 
hypertensive disease and 24 (29%) had not. 37 (44%) donors 
experienced hypotension (MAP <65 mmHg) during intensive 
care and 29 (35%) did not, data were missing from 18 (21%) 
donors.  
 
3.1 Donor intensive care and laboratory tests 
 
The median ICU stay was 36 hours (Table 6). ICU stay could not 
be calculated in 12 donors due to the lacking ICU admission time. 
The median time from brain death to organ procurement was 10 
hours. Donor laboratory values prior to organ procurement are 
presented in Table 6. 
 
 median with range 
ICU stay (days)  1 (0-13) 
ICU stay (hours)  36 (2-336) 
Time from brain death to organ 
perfusion (hours) 
10 (3-25) 
Creatinine (µmol/l) 56 (32-99) 
Hemoglobin (g/l)  120 (92-175) 
Thrombocyte count (x 10E9/l)  182 (52-434) 
thromboplastin time (%)  82 (9-152) 
Cumulative urine output 12 h before 
surgery (ml) 
 1870 (540-4150) 
Cumulative urine output during organ 
procurement (ml) 
 410 (69-2140) 
      Table 6. Donor ICU stay and laboratory values. 
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Vasoactive usage is presented in Table 7. None of the donors 
were treated with vasopressin and only one donor with 
adrenaline infusion. To treat diabetes insipidus, 66 donors 
received desmopressin and 18 did not. 
 
Vasoactive Yes No Missing data 
Noradrenaline 73 (87%)  6 (7%) 5 (6%) 
Dopamine 27 (32%) 48 (57%) 9 (11%) 
Dobutamine 9 (11%) 66 (79%) 9 (11%) 
Phenylephrine 17 (20%) 58 (69%) 9 (11%) 
Table 7. Donor vasoactive usage. 
 
 
3.2 Delayed graft function 
 
Of the 100 donated kidney grafts, 30 (30%) developed DGF. 
Patients (recipients) were  divided into  DGF and no-DGF groups, 
and these two groups were compared regarding different donor 
factors. Donor BMI (p=0,019) was statistically significantly 
different between the groups. In the DGF-group, BMI was slightly 
higher compared to no-DGF-group (Table 8). 
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 No DGF (n=70, 70%)  DGF (n=30, 30%) p-value 
Age (years) 60 (11-80) 60 (41-78) 0,322 
Creatinine (µmol/l) 56 (32-99) 54 (36-99) 0,646 
BMI (kg/m2) 25 (18-40) 26 (21-35) 0,019 
Time from brain death to 
organ perfusion (hours) 
10 (3-25) 9 (4-25) 0,575 
Cumulative urine output 12h 
before surgery (ml) 
1845 (650-4150) 1910 (540-3530) 0,479 
Cumulative urine output 
during organ procurement (ml) 
425 (70-1580) 380 (69-2140) 0,647 
ICU stay (days) 1 (0-13) 1 (0-10) 0,064 
Table 8. Continuous data presented with median and range. 
 
Categorical data is presented in Table 9 and Figure 3. Donor 
hypertension was more common (p=0,046) in the DGF-group 
(Table 9).  
 
 
 
Table 9. Categorical data compared with no DGF and DGF groups.  
 No DGF (n=70, 70%) DGF (n=30, 30%)  p-value 
Male/female 42 (66%) / 28 (78%) 22 (34%) / 8 (22%) 0,203 
Hypertension 
yes/no 
18 (56%) / 48 (76%) 14 (44%) /15 (24%) 0,046 
Kidney/multiorgan 
donor 
35 (71%) / 35 (69%) 14 (29%) / 16 (31%) 0,760 
Hypotension 
yes/no 
32 (67%) / 25 (74%) 16 (33%) / 9 (26%) 0,506 
SAH/ICH/TBI/other 19 (68%) / 20 (87%) / 
22 (61%) / 9 (69%) 
9 (32%) / 3 (13%) / 
14 (39%) / 4 (31%)  
0,206 
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Figure 3. Frequency (n) of vasoactive agent and desmopressin use in DGF and no-DGF groups. No Vasoactive 
affected DGF statistically significantly. Dopamine p=0,430, Dobutamine p=0,329, Phenylephrine p=0,185, 
Noradrenaline p=0,426, Desmopressin p=1,00. 
 
4. Discussion 
 
30 (30%) of all patients developed DGF. The incidence of DGF in 
large international registry studies has been around 25%, 
indicating our results are in accordance with previous studies4. 
In this study, donor BMI predisposed to DGF, although the 
difference in the median BMI between DGF and no-DGF -groups 
was minimal. Donor BMI is a widely acknowledged DGF risk 
factor in earlier studies. Weissenbacher et al39 showed donor 
BMI to correlate with the incidence of DGF. In their study, 
normal donor BMI 18.5-24.9 kg/m2 resulted in 31% DGF and BMI 
more than 30 resulted in 51% DGF. Obesity can be associated 
with a proinflammatory state which could lead to a greater 
immunological response during IR-injury40,41. Further research is 
needed to validate this hypothesis in organ donors.  
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In this study, donor hypertension also proved to be a statistically 
significant risk factor for DGF. Hypertension can lead to 
hypertensive nephrosclerosis, resulting in a slowly decreasing 
kidney function with proteinuria and electrolyte imbalances42. 
Donor kidneys with histological changes due to hypertension 
have a higher risk for DGF and worse 1-year graft function43.  
Despite this, Akinlolu et al. showed that a kidney graft from ECD 
donor with hypertension gave the recipient 8,5 projected extra 
life years compared to staying on dialysis44. Thus, kidney 
transplantation, compared to staying on dialysis, improves life 
expectancy even with donor hypertension as a risk factor for DGF 
and chronic allograft nephropathy. 
 
The type of brain death had no impact on DGF in this study. Some 
studies have reported non-traumatic brain death to be 
associated with DGF45,46. This might be due to poorer 
cardiovascular health in subarachnoid and intracranial 
hemorrhage patients.  
 
Donor creatinine, age and diabetes are known risk factors for 
DGF4. Diabetic donors are not generally accepted for kidney 
donation in Finland. Donor creatinine and age were not 
statistically significant predictors of DGF in this study. This might 
be due to the low number of donors. Also neither donor gender, 
hypotension or multiorgan versus kidney only donation 
correlated with DGF.  
 
Jushinskis et al47 showed that severe hemodynamic disturbances 
in the donor (asystole or hypotension with systolic pressure < 90 
mmHg) can predispose the kidney graft to DGF. In this study, 
however, hypotension (defined as MAP < 65 mmHg) did not 
predispose to DGF. 
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Vasoactive agents showed no correlation with DGF in this study. 
Protective effects of dopamine have been previously reported 
and dopamine treatment is part of the Finnish organ donor 
guideline12,17. Still, dopamine was used in only 32% of donors, 
compared with noradrenaline used in 87% of donors. In our 
material, vasoactive use varied and combinations were used. 
This shows that treatment protocols can vary between different 
hospitals despite national treatment guidelines. Due to the 
different treatment protocols and low statistical power, our 
findings on vasoactive use seem inconclusive.  
 
Urine output is used as a clinical sign of kidney function and fluid 
status. Reduced urine output reflects impaired kidney function 
or dehydration. In the donor, increased urine output implies 
diabetes insipidus or excess fluid resuscitation. In this study, the 
cumulative urine output during organ procurement and 12 hours 
prior organ procurement had no effect on DGF. However, in 19% 
of the donors diuresis was unknown due to inadequate donor 
information. Urine output is a part of UNOS donor management 
goals and achieving these goals can reduce DGF incidence up to 
50%48.  
 
In conclusion, 30 (30%) patients developed DGF, which is 
comparable to international registry studies. In this study, only 
donor BMI and hypertension were statistically significant risk 
factors for DGF. Traditional risk factors such as donor age were 
not significant in this material. Finnish treatment guidelines 
were not followed regarding vasoactive use. Noradrenaline did 
not predispose the graft to DGF, therefore it seems to be a safe 
option when donor needs vasoactive support. 
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